Iomeprol: Uses, Dosage, Side Effects and More

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Intra-arterial
Angiocardiography, Left ventriculography

Adult: As 300 mg, 350 mg or 400 mg iodine/mL solution: 30-80 mL. Max: 250 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intra-arterial
Peripheral arteriography

Adult: As 300 mg, 350 mg or 400 mg iodine/mL solution: 10-90 mL, may repeat dose as necessary. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intra-arterial
Aortography

Adult: As 350 mg or 400 mg iodine/mL solution: 50-80 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intra-arterial
Cerebral arteriography

Adult: As 250 mg or 300 mg iodine/mL solution: 5-12 mL, may repeat dose as necessary. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intra-arterial
Digital subtraction angiography

Adult: As 250 mg or 300 mg iodine/mL solution: Visceral: 2-20 mL per artery. Aorta: 25-50 mL. Peripheral: 5-10 mL per artery. All doses may be repeated as necessary. Max: 250 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intra-arterial
Coronary arteriography

Adult: As 350 mg or 400 mg iodine/mL solution: 4-10 mL per artery, may repeat dose as necessary. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intra-arterial
Visceral arteriography

Adult: As 300 mg, 350 mg or 400 mg iodine/mL solution: 5-50 mL or dose according to examination type; may repeat dose as necessary. Max: 250 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intravenous
Digital subtraction angiography

Adult: As 250 mg, 300 mg, 350 mg or 400 mg iodine/mL solution: 30-60 mL, may be repeated as necessary. Max: 250 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intravenous
Urography

Adult: As 250 mg, 300 mg, 350 mg or 400 mg iodine/mL solution: 50-150 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intravenous
Computed tomography imaging

Adult: Brain: As 250 mg, 300 mg or 350 mg iodine/mL solution: 50-150 mL. Body: As 250 mg, 300 mg, 350 mg or 400 mg iodine/mL solution: 40-150 mL. Max: 250 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Intravenous
Venography

Adult: As 250 mg, 300 mg or 350 mg iodine/mL solution: 10-100 mL, may be repeated as necessary. Max: 250 mL. Upper extremities: 10-50 mL. Lower extremities: 50-100 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Parenteral
Cavernosography

Adult: As 250 mg iodine/mL solution: 40-250 mL. As 300 mg iodine/mL solution: Up to 100 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Parenteral
Sialography

Adult: As 300 mg or 350 mg iodine/mL: 1-3 mL. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Parenteral
Myelography

Adult: As 250 mg iodine/mL: 12-18 mL via lumbar inj. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Elderly: Use the lowest effective dose.

Parenteral
Arthrography

Adult: As 300 mg or 350 mg iodine/mL solution: 1-10 mL.
Elderly: Use the lowest effective dose.

Special Precautions

Patient with history of previous reactions to contrast dye or iodinated contrast media; known clinical hypersensitivity (e.g. hay fever, food or drug allergies); asthma; history of epilepsy or increased risk of seizures (e.g. intracranial tumours, alcohol or drug use disorder); CV disease (e.g. heart failure); cerebrovascular disease (e.g. recent stroke, acute intracranial haemorrhage, brain oedema, frequent transient ischaemic attacks, acute demyelination); hyperthyroidism or goitre, multiple myeloma, myasthenia gravis, phaeochromocytoma, homozygous sickle cell disease, diabetes, polyuria, oliguria, hyperuricaemia. Ensure good hydration before and after administration. Avoid extravasation. Renal impairment; combination of renal and hepatic impairment. Elderly. Pregnancy and lactation.

Adverse Reactions

Significant: Acute kidney injury, including renal failure (particularly in patients with pre-existing renal disease); exacerbation of myasthenia gravis; may induce or aggravate ischaemia (intra-arterial inj in coronary or cerebral circulations); increased risk of seizures; encephalopathy.
Cardiac disorders: Chest pain.
Gastrointestinal disorders: Nausea, vomiting.
General disorders and administration site conditions: Feeling hot, inj site reaction (e.g. pain, warmth, discomfort).
Musculoskeletal and connective tissue disorders: Back pain, pain in extremity.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.
Skin and subcutaneous tissue disorders: Erythema, urticaria, pruritus.
Vascular disorders: Hypertension.
Potentially Fatal: Anaphylactoid reactions. Rarely, thromboembolic events causing MI and stroke; severe cutaneous adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis and drug reaction with eosinophilia and systemic symptoms.

Patient Counseling Information

Ensure adequate fluid intake before and after the procedure.

Monitoring Parameters

Correct electrolyte imbalance and dehydration before administration. Monitor renal function, blood pressure, heart rate, ECG (when clinically needed) and thyroid function (if transient hypothyroidism is noted). Assess for signs and symptoms of hypersensitivity. Observe patient for at least 30 minutes following examination.

Drug Interactions

Increased risk of lactic acidosis with metformin. May increase the risk of seizures with agents that lower the seizure threshold.

Lab Interference

May interfere with diagnostic tests using iodine-containing isotopes. High concentrations of iomeprol may interfere with test results of bilirubin, proteins or inorganic substances (e.g. Fe, Ca, phosphate, copper).

Action

Description:
Mechanism of Action: Iomeprol is a non-ionic iodinated radiocontrast agent. It allows opacification of vessels in the path of flow of contrast media, permitting radiographic visualisation of internal body structures.
Pharmacokinetics:
Excretion: Mainly via urine (90%; as unchanged drug); faeces (1.6%). Elimination half-life: 109 ± 20 minutes (IV).

Chemical Structure

Storage

Store below 30°C. Protect from light. Store away from ionising radiation.

MIMS Class

Radiographic & Diagnostic Agents

ATC Classification

V08AB10 - iomeprol ; Belongs to the class of watersoluble, nephrotropic, low osmolar preparations used as X-ray contrast media.

References

Brayfield A, Cadart C (eds). Iomeprol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/01/2025.

Iomeprol. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 17/01/2025.

Iomeprol. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 17/01/2025.

Iomeron 250, Solution for Injection (Bracco UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 17/01/2025.

Iomeron 300, Solution for Injection (Bracco UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 17/01/2025.

Iomeron 350, Solution for Injection (Bracco UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 17/01/2025.

Iomeron 400 Injection (DCH Auriga [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 23/04/2025.

Iomeron 400, Solution for Injection (Bracco UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 17/01/2025.

Iomeron Injection, Solution (Bracco Diagnostics Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 17/01/2025.

Regional Health Limited. Iomeron Solution for Injection 300 mg iodine/mL, 350 mg iodine/mL, and 400 mg iodine/mL data sheet 19 March 2019. Medsafe. http://www.medsafe.govt.nz. Accessed 17/01/2025.

Disclaimer: This information is independently developed by MIMS based on Iomeprol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com